MapLight (MPLT) CAO Jonathan Gillis Receives RSUs & Options

What Happened
Jonathan Gillis, Chief Accounting Officer and Interim CFO of MapLight Therapeutics (MPLT), received equity compensation on August 17, 2026. The Form 4 reports awards (transaction code A) totaling 35,510 underlying shares: 8,242 RSUs (6,020 + 2,222) and 27,268 option-type derivative awards (24,455 + 2,813). All grants were reported at $0.00 (awarded/issued, not purchased or sold).

Key Details

• Transaction date: 2026-08-17; Form 4 filed 2026-08-19 (filed within required reporting period).
• Reported amounts: 6,020 RSUs; 2,222 RSUs; 24,455 derivative shares (option); 2,813 derivative shares (option) — total 35,510 underlying shares.
• Price: $0.00 per share (award/grant). Transaction code: A (award/grant).
• Shares owned after transaction: Not disclosed in the Form 4.
• Notable footnotes:
  • RSUs: Each RSU converts to one share on vesting. One RSU grant vests 1/4 on July 1, 2027 then quarterly in 1/16 increments thereafter; another RSU grant vests in eight equal quarterly installments starting Oct 1, 2026.
  • Options/derivative awards: One option grant vests 1/4 on July 1, 2027 then 1/48th monthly thereafter; the other option grant vests in 24 equal monthly installments starting Aug 1, 2026. Vesting is subject to continued service.
• No indication these awards were exercised, sold, or part of a 10b5-1 plan in the filing.

Context
These entries are compensation grants, not open-market purchases or sales. RSUs and option awards typically vest over time and convert to shares only if vesting conditions are met (here, continued service). Such awards do not involve cash payment by the insider at grant and do not by themselves signal immediate buying or selling of stock.